Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Complix Appoints Dr Yvonne McGrath as CSO

Published: Saturday, May 17, 2014
Last Updated: Saturday, May 17, 2014
Bookmark and Share
Dr McGrath will be responsible for the use of the Company´s Alphabody platform.

Complix has announced that it has appointed Yvonne McGrath as Chief Scientific Officer (CSO).

As CSO of Complix, Dr McGrath will be responsible for the use of the Company´s Alphabody platform to identify new drug candidates and take these forward into development, either internally or with partners.

This is part of Complix´ wider goal to build a pipeline of transformative Alphabody protein therapeutics. Dr Ignace Lasters, previously CSO and co-founder of Complix, will assume the role of Chief Technology Officer (CTO), and will be responsible for the further development and expansion of the Alphabody technology platform.

Dr McGrath was most recently at Immunocore as Head of Development and before that as Head of Preclinical Development and CMC. In these positions, she successfully developed and executed the late preclinical and early clinical strategy for a novel platform technology, managed meetings with European and US regulatory authorities and led manufacturing and CMC strategy for a new biological entity targeting cancer.

Dr McGrath’s previous experience includes being a Project Manager at the UK subsidiary of the German biotech company MediGene AG, and Senior Scientist at BioVex (now part of Amgen). She has a PhD from the University of Wales, College of Medicine.

Dr Mark Vaeck, CEO of Complix, said: “I am delighted to welcome Yvonne to strengthen our management team, as we enter an exciting phase in Complix’ development. We are continuing to generate promising data with our lead oncology anti-MCL-1 program, which has shown that CPABs can exert potent activity against an important intracellular cancer target. Yvonne’s expertise in the preclinical and early clinical development of novel platform technologies will be a great asset to the Company as we seek to expand and accelerate our CPAB programs.”

Dr McGrath, commenting on her appointment, said: “I have been very impressed with the potential of Complix’ unique Alphabody platform. CPABs clearly have the potential to transform drug development by being able to reach a range of important intracellular disease targets which are known but cannot be addressed with existing protein therapeutics. I am excited to be a key member of the Complix team and look forward to taking a number of CPABs into the clinic.”

It is estimated that there are more than 1000 intracellular disease targets which are known to be involved in important disease processes, but are currently undruggable by conventional therapeutics. Complix’ CPABs have the unique capacity to enter cells effectively and modulate intracellular protein-to-protein interactions (PPIs).

The Company has generated compelling data with its lead program against the intracellular cancer target MCL-1. MCL-1 is an important regulator of cellular apoptosis and is often over-expressed in cancer cells thereby preventing them from dying.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Complix Raises €12 Million (US$15.5 million) in Series B Round
Financing to advance Alphabodies™, a unique class of protein therapeutics active against intracellular disease targets.
Wednesday, June 26, 2013
Complix Receives €1.9 Million IWT Grant
Grant to accelerate development of Alphabodies™ against intracellular disease targets, including cancer.
Tuesday, October 30, 2012
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!